News Sentiment

GDTC sentiment intelligence

CytoMed Therapeutics Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.03 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+5.6% over one week, -9.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 5.6% Price confirming higher
Trend fit Trend inactive -9.6% over four weeks
Fair value -54.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingKey 7
Market source 5
dars.gov.et 4
TradingView 4
Moomoo 3
Finviz 3
FinancialContent 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 13
Deals and strategy 6
Guidance 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
FinancialContent Direct company coverage

CytoMed Therapeutics Ltd – An Emerging Star in Singapore’s Cancer Biotechnology Sector

CytoMed Therapeutics Ltd, a clinical-stage biotech company spinning off from ASTAR, is developing affordable cancer therapies using allogeneic Gamma Delta T Cells. The company's strategy involves leveraging lower costs in Southeast Asia, partnering with hospitals, and focusing on

Tone
Positive 73/100
Event
Market update
Published
15 Jul 2026 17:41
Source
FinancialContent
Moomoo Direct company coverage

CytoMed Therapeutics (GDTC) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for CytoMed Therapeutics (GDTC). It includes key metrics such as the stock price, market cap, 52-week range, volume, and average volume. The article also touches upon the company's financial performance, analyst price tar

Tone
Neutral 50/100
Event
Guidance
Published
10 Jul 2026 16:41
Source
Moomoo
FinancialContent Direct company coverage

CytoMed Therapeutics Ltd (NASDAQ: GDTC) – A Rising Star in Singapore’s Cancer Biotechnology Sector

CytoMed Therapeutics Ltd (NASDAQ: GDTC), a clinical-stage biotech company, is making strides in developing affordable cancer therapies using patented allogeneic Gamma Delta T Cells. The company is currently conducting clinical trials in Singapore and plans to expand to Malaysia,

Tone
Positive 77/100
Event
Market update
Published
09 Jul 2026 18:39
Source
FinancialContent
Finviz Direct company coverage

GDTC - CytoMed Therapeutics Ltd Options

This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its last close price, market capitalization, income, sales, key financial ratios, and stock performance metrics. It lists various operational and financial indicators, such as ROA, R

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 16:09
Source
Finviz
Finviz Direct company coverage

GDTC - CytoMed Therapeutics Ltd Volatility & Greeks

This article provides a detailed financial overview of CytoMed Therapeutics Ltd (GDTC), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's volatility and various financial ratios, offering a snapsho

Tone
Negative 38/100
Event
Market update
Published
03 Jul 2026 18:40
Source
Finviz
The Globe and Mail Direct company coverage

CytoMed Chairman Boosts Personal Stake and Funds R&D Expansion at LongevityBank

CytoMed Therapeutics chairman, Choo Chee Kong, is increasing his personal stake in the company by acquiring up to 200,000 shares and also invested S$300,000 in CytoMed’s subsidiary, LongevityBank Pte Ltd, through his wholly owned EP Capital Inc. This investment will double EP Cap

Tone
Positive 67/100
Event
Deals and strategy
Published
27 Jun 2026 16:09
Source
The Globe and Mail
Investing.com Direct company coverage

Form 6K CytoMed Therapeutics Ltd For: 23 June

This article announces the filing of Form 6K by CytoMed Therapeutics Ltd for June 23. It includes disclaimers about the high risks involved in trading financial instruments and cryptocurrencies, emphasizing that data may not be real-time or accurate and that investors should be f

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 22:10
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 6K CytoMed Therapeutics Ltd For: 23 June By Investing.com

This article provides details of a Form 6K filing by CytoMed Therapeutics Ltd for June 23. The content is brief, primarily serving as a notification of the filing, and includes general financial market data such as indices, commodities, bonds, and shares, which are not directly r

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 17:24
Source
Investing.com Nigeria
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D

CytoMed Therapeutics' Chairman and Director, Choo Chee Kong, plans to acquire up to 200,000 company shares through private cash transactions, demonstrating increased personal exposure to the stock. Separately, his entity, EP Capital Inc., invested S$300,000 (approximately US$250,

Tone
Positive 66/100
Event
Balance sheet
Published
23 Jun 2026 16:10
Source
Stock Titan
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CytoMed Therapeutics Ltd (GDTC), focusing on support, resistance, indicators, and moving averages. It synthesizes various technical indicators like MACD, RSI, and MA to offer a comprehensive outlook. The analysis indicates a "Sell" si

Tone
Negative 40/100
Event
Guidance
Published
18 Jun 2026 08:11
Source
TradingKey
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Valuation: PE, PB & Fair Value Analysis

This article provides an analysis of CytoMed Therapeutics Ltd (GDTC) valuation metrics, specifically Price-to-Earnings (P/E), Price-to-Book (P/B), and Fair Value. It explicitly states that relevant data for P/E, P/B, P/S, and P/CF have not yet been disclosed by the company. The p

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:39
Source
TradingKey
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for CytoMed Therapeutics Ltd (GDTC), focusing on future EPS and revenue growth estimates. It notes that relevant data has not yet been disclosed by the company, thus no forecast figures are available. However, analysts forecast a price t

Tone
Positive 60/100
Event
Earnings
Published
18 Jun 2026 06:08
Source
TradingKey
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Institutional Confidence

This article provides details on the institutional confidence in CytoMed Therapeutics Ltd (GDTC), including its stock performance, market capitalization, and key institutional shareholders. It lists several institutional investors and individual shareholders, along with their sha

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 06:08
Source
TradingKey
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for CytoMed Therapeutics Ltd (GDTC), focusing on its volatility, financial risk, and investment risk. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return-to-Drawdown Ratio, Skewness, Sharpe Ratio, a

Tone
Negative 40/100
Event
Market update
Published
18 Jun 2026 03:40
Source
TradingKey
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for CytoMed Therapeutics Ltd (GDTC), focusing on its business segments, regional revenue, and profit contribution. It states that relevant data for these categories have not yet been disclosed by the company. The page also includes current

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 20:40
Source
TradingKey
TradingKey Direct company coverage

CytoMed Therapeutics Ltd (GDTC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of CytoMed Therapeutics Ltd's (GDTC) shareholder structure, detailing major shareholders and institutional holdings. It lists the proportion held by key entities like Glorious Finance Limited and mDR Limited, alongside a breakdown by shareholder

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:40
Source
TradingKey
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) director buys 112,000 shares in open market

CytoMed Therapeutics director and ten percent owner Choo Chee Kong purchased 112,000 Ordinary Shares in an open-market transaction at $1.1498 per share, totaling $128,778. Following this acquisition, Choo Chee Kong directly owns 430,324 Ordinary Shares. The filing indicates a pos

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Jun 2026 10:40
Source
Stock Titan
Simply Wall Street Direct company coverage

CytoMed Therapeutics (Nasdaq:GDTC) - Stock Analysis

This article provides a stock analysis of CytoMed Therapeutics (Nasdaq:GDTC), highlighting its status as a clinical-stage biopharmaceutical company focused on cell-based immunotherapies. It details the company's financial performance, including declining earnings and an undervalu

Tone
Negative 38/100
Event
Earnings
Published
05 Jun 2026 02:09
Source
Simply Wall Street
Stock Titan Direct company coverage

CytoMed Therapeutics (NASDAQ: GDTC) shareholders approve all AGM proposals

CytoMed Therapeutics (NASDAQ: GDTC) shareholders approved all ten proposals at its Annual General Meeting (AGM) held on May 22, 2026, in Singapore. These approvals included adopting financial statements, re-electing directors Dr. Yew Chak Hua and Dr. Toh Keng Kiat, waiving the Si

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 19:40
Source
Stock Titan